Prosecution Insights
Last updated: April 19, 2026

Examiner: LANKFORD JR, LEON B

Tech Center 1600 • Art Units: 1651 1657 1692

This examiner grants 70% of resolved cases

Performance Statistics

69.5%
Allow Rate
+9.5% vs TC avg
748
Total Applications
+30.6%
Interview Lift
1459
Avg Prosecution Days
Based on 714 resolved cases, 2023–2026

Rejection Statute Breakdown

6.6%
§101 Eligibility
16.4%
§102 Novelty
39.4%
§103 Obviousness
25.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18294902 Compositions, Systems and Methods for Atom Transfer Radical Addition Reaction Non-Final OA The Regents of the University of California
18268177 MEANS AND METHODS FOR MANUFACTURING RACEMIC ALANINE FOR THE MGDA SYNTHESIS Non-Final OA BASF SE
18236366 TRAINED NEURONAL CELL CULTURES FOR DRUG TESTING Non-Final OA MICROSOFT TECHNOLOGY LICENSING, LLC
17800320 GENERATING AORTA-GONAD-MESONEPHROS-LIKE HEMATOPOIETIC CELLS FROM HUMAN PLURIPOTENT STEM CELLS UNDER A DEFINED CONDITION Non-Final OA Purdue Research Foundation
16961189 IMMUNE CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR Non-Final OA The General Hospital Corporation
17600931 DUAL ANTIGEN-RECOGNIZING iPS CELL-DERIVED CHIMERIC ANTIGEN RECEPTOR-T-CELL THERAPY Non-Final OA THE UNIVERSITY OF TOKYO
18690537 POLYSACCHARIDE OR POLYSACCHARIDE MIXTURE PRODUCED BY PAENIBACILLUS POLYMYXA Non-Final OA Technische Universität München
17768016 GENETICALLY MODIFIED HUMAN STEM CELL EXPRESSING A MUTANT HUMAN CYTOCHROME P450 2B6 PROTEIN AND USE THEREOF IN THE TREATMENT OF CANCER Non-Final OA SORBONNE UNIVERSITE
17194761 METHOD FOR INDUCING ALVEOLAR EPITHELIAL PROGENITOR CELLS Non-Final OA KYOTO UNIVERSITY
18775257 HUMAN IPSC-DERIVED VASCULAR-RELATED AND HEMATOPOETIC CELLS FOR THERAPIES AND TOXICOLOGY/DRUG SCREENINGS Final Rejection The USA, as represented by the Secretary, Department of Health and Human Services
18555348 MAINTENANCE AND/OR CULTURE OF TISSUE SLICES IN VITRO OR EX VIVO Non-Final OA SINGAPORE HEALTH SERVICES PTE LTD
18621330 NOVEL PROTEASES AND USES THEREOF Non-Final OA CARBIOS
18577139 Crystal Structures of ALK and LTK Receptor Tyrosine Kinases and Their Ligands Non-Final OA Universiteit Gent
18451280 CELL PENETRATING PEPTIDE, CONJUGATE COMPRISING SAME, AND COMPOSITION COMPRISING CONJUGATE Non-Final OA GemVax & KAEL CO., LTD.
18482834 MICROORGANISMS AND METHODS FOR PRODUCING (3R)-HYDROXYBUTYL (3R)-HYDROXYBUTYRATE Non-Final OA Genomatica, Inc.
18553316 LIVER ORGANOID MANUFACTURING METHODS, LIVER ORGANOIDS OBTAINED WITH THE SAME, AND USES THEREOF Non-Final OA CHU DE NANTES
18550130 IMMUNE ENHANCERS Final Rejection Deutsches Krebsforschungszentrum
17865875 ANTI-FIBROSIS AGENT AND METHOD OF PRODUCING EXTRACELLULAR VESICLE HAVING ANTI-FIBROSIS ACTION Non-Final OA FUJIFILM Wako Pure Chemical Corporation
18546864 DNASE 1-LIKE 2 ENGINEERED FOR MANUFACTURING AND USE IN THERAPY Non-Final OA Neutrolis, Inc
17789378 APPLICATION OF CST1 IN PREVENTION AND/OR TREATMENT OF LIVER IMMUNE DYSREGULATION DISEASES Non-Final OA CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES
18035549 METHODS FOR SYSTEMATICALLY ASSESSING LOCAL INFLAMMATION AND ACTIVE REPAIR Non-Final OA KEYINTEL MEDICAL INC.
17747468 Inhibitors of DREAM Complex Assembly and/or Function For Use In Repairing DNA Damage Non-Final OA Björn Schumacher
17762978 METHOD FOR MANUFACTURING REPAIRING AGENT FOR BIOLOGICAL TISSUE DAMAGE, AND REPAIRING AGENT FOR BIOLOGICAL TISSUE DAMAGE Non-Final OA Hiroshima University
16962686 Polymer-Encapsulated Viral Vectors for Genetic Therapy Final Rejection aratinga.bio TNP

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month